Saturday, October 2nd

Central Europe Summer Time (CEST)

Moderator: Jesús F. San-Miguel
09:00 - 09:20How I treat relapsed patients (without immunotherapy)
Mario Boccadoro
09:20 - 09:35Experts' discussion on 5 burning topics:
1. Biological relapse versus agresive relapse
2. Early and late relapse and ASCT
3. Triplet versus doublets: is it cost-effective?
4. Optimal sequence for new agents
5. Extramedullary relapse
Discussants: Mario Boccadoro, Meletios A. Dimopoulos, Mohamad Mohty, Paula Rodríguez-Otero
Moderator: Heinz Ludwig
09:45 - 10:05Bases for immunotherapy in MM and novel antibodies
Hermann Einsele
10:05 - 10:25Clinical results with CAR-T cells and other adoptive therapies
Paula Rodríguez-Otero
10:25 - 10:40Experts' discussion on 6 burning topics:
1. Role of conjugated antibodies
2. Sequence of anti-BCMA treatments
3. Is CAR-T the future?
4. CAR-T plus anti-myeloma drugs
5. Bispecific antibodies or CAR-T
6. Industry or academia
Discussants: Hermann Einsele, Paula Rodríguez-Otero, Meletios A. Dimopoulos, Mohamad Mohty
Moderator: Jesús F. San-Miguel, Heinz Ludwig
10:50 - 11:10Amyloidosis
Giampaolo Merlini
11:10 - 11:30Waldenstrom macroglobulinemia
Meletios A. Dimopoulos
11:30 - 11:50The relations between academia and industry
Mohamad Mohty
11:50 - 12:05Questions & discussion
Jesús F. San-Miguel, Heinz Ludwig